Topotecan HCl

Catalog No.S1231 Synonyms: NSC609699, Nogitecan HCl, SKFS 104864A

Topotecan HCl Chemical Structure

Molecular Weight(MW): 457.91

Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 180 In stock
USD 320 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

2 Customer Reviews

  • Cells were treated at the same concentrations as in Caspase3/7 assay for 16 hours and total cell lysates were prepared for Western blotting. GAPDH was used as a loading control.

    BMC Cancer, 2015, 10.1186/s12885-015-1231-z. Topotecan HCl purchased from Selleck.

    Pax3:Foxo1a knockdown increases select chemotherapy sensitivities. MTS assay was performed for Pax3:Foxo1a knockdown mouse aRMS tumor cells treated with DNA damaging agents and microtubule inhibitors. Pax3:Foxo1a knockdown reduced the concentration at which viability was impaired by 50% (IC50) of topotecan by 4.8 fold, respectively, yet did not affect the IC50 of mafosfamide.

    PLoS Genet 2014 10(1), e1004107. Topotecan HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.
Features Topotecan is a water-soluble derivative of camptothecin.
Targets
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
In vitro

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells MWLDfZRwfG:6aXRCpIF{e2G7 NVTXc21mPzJiaB?= MofUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDpZ|UxRTFibl2= M2i2cFIxOzdzMUiz
human Bel7402 cells M3\0e2N6fG:2b4jpZ:Kh[XO|YYm= NHnvTWw6PiCq NHLBNWxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBD\Wx5NECyJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5{IH7N NHm2OmwyPTF4NUG0OC=>
human HCT8 cells M2jsPWN6fG:2b4jpZ:Kh[XO|YYm= MYK5OkBp NW\k[VB5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWODDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvPSCwTR?= NIjZVHQyPTF4NUG0OC=>
human MCF7 cells MoDaR5l1d3SxeHnjxsBie3OjeR?= NUjITVl5QTZiaB?= NFfmV|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU45KG6P MmK1NVUyPjVzNES=
human A549 cells MnOxR5l1d3SxeHnjxsBie3OjeR?= M3fzelk3KGh? MlPJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOuNkBvVQ>? NWW4bVY6OTVzNkWxOFQ>
human colon carcinoma SW620 cell M1SxXmN6fG:2b4jpZ:Kh[XO|YYm= M{exWGN6fG:2b4jpZ{Bxd3SnboTpZZRqd25ib3[gWI9xd3SnY3HuJEhVWCliYomgeIhmKGOxbYDveY5lKGmwIHj1cYFvKGOxbH;uJINiemOrbn;tZUBUXzZ{MDDj[YxtKGyrbnWsJGlEPTB;Mz6yJI5O NEiyenEyOjRyOEewOy=>
human MESSA cells M1;0dWN6fG:2b4jpZ:Kh[XO|YYm= MWC3NkBp M4LWS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GW1ODIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME20JI5O M{ewZ|IyOzRzNke0
human BGC823 cells MVfDfZRwfG:6aXRCpIF{e2G7 NXG5UYQyQTZiaB?= MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20MlMhdk1? NIXLbYUyPTF4NUG0OC=>
human Ketr3 cells M33qUWN6fG:2b4jpZ:Kh[XO|YYm= NFPnXms6PiCq MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDL[ZRzOyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUSuPUBvVQ>? NEnSTJUyPTF4NUG0OC=>
LOX cells NYn5Ono6S3m2b4TvfIlkyqCjc4PhfS=> Ml31R5l1d3SxeHnjbZR6KHejczDk[ZRmem2rbnXkJIlvKH[rdILvJIlvKEyRWDDj[YxteyBqbXXsZY5wdWFrIH;mJIh2dWGwIIT1cY9zKGOnbHygcIlv\XNiYomgeZNqdmdiTWTUJIF{e2G7LDDJR|UxRTVibl2= Mlj2O|g2OzN|MR?=
human A549 cells NYDpfVF{TnWwY4Tpc44h[XO|YYm= M4fMVFQhcA>? Mmi3RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PSCwTR?= MlvhNVgzODd5NEi=
human H69 cells M4rvVmN6fG:2b4jpZ:Kh[XO|YYm= M4G2TlczKGh? M4XI[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg3QSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;NjDuUS=> MX2yNVM1OTZ5NB?=
human A2780 cells NGf5UWxEgXSxdH;4bYPDqGG|c3H5 NWTS[IRkPzJiaB?= MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDhcJBp[TWkZYThN{BqdnSnZ4LpckBie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;NjDuUS=> MWeyNlk2QTJ2Nh?=
human LNCAP cells NUPjbGZZS3m2b4TvfIlkyqCjc4PhfS=> MVS3NkBp NFyzeY1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9PUBvVQ>? NHm3SJEzOTN2MU[3OC=>
human HOP62 cells MlLES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXzHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIU3A3OiClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? NFL4RlgzPTlyOUK3PS=>
human MCF7 cells M{S1XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWrXUmNjT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFnDOVA:OTBibl2= MUeyOVkxQTJ5OR?=
human UACC62 cells M1jNWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoXNS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWWFESzZ{IHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiSVO1NF0yOCCwTR?= NHHrXZYzPTlyOUK3PS=>
human DU145 cells MlzmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? NUTvVppFOjV7MEmyO|k>
LoVo cell line MXnDfZRwfG:6aXRCpIF{e2G7 MlzsR5l1d3SxeHnjJJBwfGWwdHnheIlwdiCxZjDUc5BwfGWlYX6gLHRRMSCkeTD0bIUh[2:vcH;1coQhcW5iKHj1cYFvKGOxbH;y[YN1[WxiY3HuZ4VzKEyxVn:gZ4VtdCCuaX7lMEBKSzVyPUGxMlYhdk1? MWSxNlQxQDdyNx?=
human lymphoblast tumor cell line RPM18402 NF\6SZhEgXSxdH;4bYPDqGG|c3H5 MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDsfY1xcG:kbHHzeEB1fW2xcjDj[YxtKGyrbnWgVnBOOTh2MEKsJGlEPTB;MUKgcm0> MXuxNlM6Ojd2NR?=
human HL60 cells NXTySlFpTnWwY4Tpc44h[XO|YYm= NVXlc3RYSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{BjgSCVUlKgcYV1cG:mLDDJR|UxRTF{IH7N NUXCU4tIOTl3NEG0PFM>
human A375 cells NF3CbVlEgXSxdH;4bYPDqGG|c3H5 NVfSWVZzPzJiaB?= M4rOS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUGzJI5O NHPZWXUzOTN2MU[3OC=>
COR-L23/P cell MmG2R5l1d3SxeHnjxsBie3OjeR?= MUTDfZRwfG:6aXPpeJkhdWWjc4Xy[YQhfXOrbnegeIhmKEORUj3MNlMheGG{ZX70ZYwhMEORUj3MNlMwWCliaIXtZY4hdm:wIIPtZYxtKGOnbHygcJVv\yClYYLjbY5wdWFiY3XscEBtcW6nLDDJR|UxRTF|LkKgcm0> NInRbYgyOThyNkeyOC=>
human NCI-H460 cells NXvRbmt4WHKxbHnm[ZJifGmxbjDhd5NigQ>? NULmZYJ3PzJiaB?= NVv0Uoo{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2:3bITldkBkd3WwdHXyJIFv[Wy7c3nzMEBKSzVyPUG2JI5O MlPnNlE4QDN|Nkm=
human MOLT4 cells NXe4RWxnS3m2b4TvfIlkyqCjc4PhfS=> NGDDNJo4OiCq MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUG5JI5O M1z1Z|I1QTByN{K1
human LoVo cells NFXUXZZEgXSxdH;4bYPDqGG|c3H5 M{\vSlczKGh? M4iwfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxwXm9iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yNEBvVQ>? MnrZNlA{PzFzOEO=
RPM18402 tumor cell line NUXqeZd1WHKxbHnm[ZJifGmxbjDhd5NigQ>? NYWwelNbS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JINmdGxicILvcIln\XKjdHnvckBqdiCUUF2xPFQxOiC2dX3vdkBk\WyuIHzpcoUtKEmFNUC9NlAhdk1? MVOxOVQ5Ojl{OR?=
human SN12C cells M1KyW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M17E[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNPOTKFIHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiR1m1NF0zOCCwTR?= Ml7hNlU6ODl{N{m=
human RPMI8226 cells NWX1XpVCS3m2b4TvfIlkyqCjc4PhfS=> NXTURWxlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWlCPSUiyNlYh[2WubIOgZpkhVVSWIH3leIhw\CxiSVO1NF0zOSCwTR?= MVWxPVAyOjl7Nh?=
HT-29 cells M4nZVGN6fG:2b4jpZ:Kh[XO|YYm= NWfKcIhnS3m2b4TvfIlkcXS7IIfhd{Bl\XSncn3pcoVlKGmwII\peJJwKGmwIFjUMVI6KGOnbHzzLINwdG:wKTDv[kBpfW2jbjD0eY1weiClZXzsJIxqdmW|IHL5JJV{cW6pIF3UWEBie3OjeTygTWM2OD1{NTDuUS=> M1frfVc5PTN|M{G=
SK-BR-3 cells NVjwfpB[S3m2b4TvfIlkyqCjc4PhfS=> NFLNXppKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIwhdGmwZTCoV2suSlJvMzmsJGlEPTB;Mk[gcm0> Mo[3NVE{OzR3Nkm=
HeLa cells MlHXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2\hWWdzd3e2aDDpcohq[mm2aX;uJI9nKEinTHGgZ4VtdHNiYX\0[ZIhPCCmYYnzMEBIUTVyPUOwJI5O Mlz6NVc1OTh3OEK=
UACC 62 cells Mn7XR5l1d3SxeHnjxsBie3OjeR?= MVfU[ZN1\WRiaX6geol1em9iZn;yJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJR2dW:{IHPlcIwhdGmwZTDVRWNEKDZ{IDjt[Yxidm:vYTmsJGdKPTB;M{Cgcm0> MoftNVA4OTR3MEK=
human HCT116 cells M2[wbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCJSUWwQVMxKG6P M{fhblI2QTB7Mke5
human lung cancer cell line (H128) MojSR5l1d3SxeHnjxsBie3OjeR?= NHnrT4NKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtfW6pIHPhcoNmeiClZXzsJIxqdmViKFixNlgqNCCLQ{WwQVMyKG6P NWC3UIJwOTF|M{S1Olk>
human MES-SA/Dx5 cells NITMbXBEgXSxdH;4bYPDqGG|c3H5 MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FxRIi1JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKE2GUkGgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTN|IH7N MX2yNVM1OTZ5NB?=
human A2780 cells MVPDfZRwfG:6aXRCpIF{e2G7 MmrEO|IhcA>? M{LufmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9N|Mhdk1? NILsV3czPDlyMEeyOS=>
human MDA-MB-435 cells NFG4Um1EgXSxdH;4bYPDqGG|c3H5 MoH4O|IhcA>? NEXRVWpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OD1|NDDuUS=> MkDhNlI5PjdyMUm=
human stomach cancer cell line (MKN45) MUfDfZRwfG:6aXRCpIF{e2G7 M{HTfWlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJN1d22jY3igZ4Fv[2W{IHPlcIwhdGmwZTCoUWtPPDVrLDDJR|UxRTN6IH7N Ml7vNVE{OzR3Nkm=
human KB3-1 cells MojZR5l1d3SxeHnjxsBie3OjeR?= MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NECgcm0> NGLJNVEyQDh{OUOzOC=>
mouse P388 cells NYH3Nm9sS3m2b4TvfIlkyqCjc4PhfS=> MnLpR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgVFM5QCClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NEWgcm0> NYnFZ4VMOTh6MkmzN|Q>
A427 human lung carcinoma NXz0Z4FFWHKxbHnm[ZJifGmxbjDhd5NigQ>? NHXGeFhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBu\WG|dYLl[EBi\2GrboP0JGE1OjdiaIXtZY4hdHWwZzDjZZJkcW6xbXGsJGlEPTB;NEmgcm0> MnviPVg4PjFzMR?=
human U251 cells NFHjXJlHfW6ldHnvckBie3OjeR?= MVu2MVI1KGh? MUDJcohq[mm2aX;uJI9nKHSxcH;pd49u\XKjc3WtNUBqdiCqdX3hckBWOjVzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhcHmyb4jpZU1qdmS3Y3XkJGhKTi1zYXzwbIEh[WOldX31cIF1cW:wIHnuJI52[2ynYYKg[Zh1emGldDDh[pRmeiB4IITvJFI1KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{NCCHQ{WwQVU1KG6P Mk\qNlI{ODV4MUK=
human colon cancer cell line (WiDr) NVTJVFZyS3m2b4TvfIlkyqCjc4PhfS=> MmG2TY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9OVYhdk1? NHfEOFgyOTN|NEW2PS=>
human HepG2 cells MlzPR5l1d3SxeHnjxsBie3OjeR?= M3nmcFQh\GG7cx?= NEHLNZhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA1KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVYxKG6P NIm0NWwyQDV3NEmwOi=>
human KB cells NGDDVGJEgXSxdH;4bYPDqGG|c3H5 NIOzOVg4OiCq MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMhe3WuZn;ybI9l[W2rbnWgRkBkd2yxcnnt[ZRzcWNiYYPzZZktKEmFNUC9OlIvPSCwTR?= MluxNlUxODh2NU[=
human HCT8 cells M3zMWWN6fG:2b4jpZ:Kh[XO|YYm= NXqyTopROyCmYYnz NETrcopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9O|Ahdk1? M1HBcFIxOzl{NUS1
human GBM2 cells MXHQdo9tcW[ncnH0bY9vKGG|c3H5 M2K2blczKGh? NUTGXJBxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHRm0zKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RvMTDt[ZRpd2RuIFnDOVA:OC5zMzFOwG0> NXfh[VhnOjZ|NUW1N|I>
SK-MEL-2 cells MWTDfZRwfG:6aXRCpIF{e2G7 NGr5[WE4OiCq NEi1fHFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2PRVytNkBk\WyuczDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVA:OC5zNDFOwG0> M{PPdlIyOzRzNke0
human IGROV1 cells NFnKWlZEgXSxdH;4bYPDqGG|c3H5 MW[3NkBp M4rpTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlIWk:YMTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9NE4yPiEQvF2= MlLtNlE{PDF4N{S=
human U87 cells M4ftfHBzd2yrZnXyZZRqd25iYYPzZZk> NV\k[3FOPDhiaB?= NH\SNpZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVYh|ryP NWHNVXpvOjR6Mk[4NVg>
human HT1080 cells NYHVNoVIWHKxbHnm[ZJifGmxbjDhd5NigQ>? NWjM[2ZrPDhiaB?= MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMUC4NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwQVAvOThizszN M4rWOVI3PDB6OEG1
human Hep3B cells NWiyVnd2WHKxbHnm[ZJifGmxbjDhd5NigQ>? NYnE[ZJ1PzJiaB?= MlWxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYCzRkBk\WyuczDh[pRmeiB5MjDodpMh[nliWGTUJIF{e2G7LDDHTVUxRTBwMkKg{txO MmLNNVk4QTZ7NU[=
human GBM3 cells M1zGeHBzd2yrZnXyZZRqd25iYYPzZZk> MWi3NkBp NY\Jb|A6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHRm0{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RvMTDt[ZRpd2RuIFnDOVA:OC5|ODFOwG0> NFjJNJAzPjN3NUWzNi=>
human KBVIN cells MXXDfZRwfG:6aXRCpIF{e2G7 NG[0Now4OiCq M{[zNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDXkmQIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE41KM7:TR?= NUKwdJRbOjV2M{i3Olk>
human GBM1 cells M{f5ZXBzd2yrZnXyZZRqd25iYYPzZZk> M3zVPVczKGh? Mni3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2xJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9NE41PiEQvF2= NFTKU2EzPjN3NUWzNi=>
human U937 cells M1TZO2N6fG:2b4jpZ:Kh[XO|YYm= MWS0PEBp NIrjToVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{KGW6cILld5NqdmdicEWzJI12fGGwdDDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7IP-8kEBKSzVyPUGuNUDPxE1? Mk[yNVk4OTV|MUm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3 / p62 ; 

PubMed: 23024792     


The indicated cells were treated with the indicated concentrations of topotecan for 24 h. The lysates were analysed by immunoblotting with The LC3 and P62 antibodies.

p53 / sesn2 / p-AMPK ; 

PubMed: 23024792     


HCT116 and LS-174T cells were treated with various concentrations of TPT for 24 h. The levels of P53, sestrin2 and p-AMPK were analysed by immunoblotting. 

23024792
Growth inhibition assay
Cell viability ; 

PubMed: 28544814     


Dose-response curves for topotecan (panel A) were determined in neuroblastoma cell lines The IC50 for the drugs are indicated. Changes in LAN-1 cell viablity as a function of different topotecan exposure times (panel B) were determined.

28544814
In vivo Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7 Luc and DU-145 Luc cells
  • Concentrations: 0 μg/mL - 0.692 μg/mL
  • Incubation Time: 96 hours
  • Method:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice with MCF-7 Luc or DU-145 Luc cells
  • Formulation: PBS
  • Dosages: 0.25 mg/mL
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL (198.72 mM)
Water 91 mg/mL (198.72 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 457.91
Formula

C23H23N3O5.HCl

CAS No. 119413-54-6
Storage powder
in solvent
Synonyms NSC609699, Nogitecan HCl, SKFS 104864A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04022876 Not yet recruiting Drug: ALRN-6924|Drug: Topotecan Small-cell Lung Cancer Aileron Therapeutics August 2019 Phase 1|Phase 2
NCT03927274 Recruiting Drug: Topotecan Glioma of Brain H. Lee Moffitt Cancer Center and Research Institute April 23 2019 Early Phase 1
NCT03107988 Recruiting Drug: Lorlatinib|Drug: Cyclophosphamide|Drug: Topotecan Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|Pfizer|University of Southern California|Solving Kids'' Cancer US/EU|Children''s Neuroblastoma Cancer Foundation|The Band of Parents|The Evan Foundation|Wade''s Army|Ronan Thompson Foundation|The Catherine Elizabeth Blair Memorial Foundation|Cookies for Kids'' Cancer September 1 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

  • Answer:

    Topotecan HCl is generally prepared by Saline for I.P. administration.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Topotecan HCl | Topotecan HCl supplier | purchase Topotecan HCl | Topotecan HCl cost | Topotecan HCl manufacturer | order Topotecan HCl | Topotecan HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID